UCB
Biopharma firm developing treatments for severe neurological and immunological diseases.
UCB | BR
Overview
Corporate Details
- ISIN(s):
- BE0002730118 (+5 more)
- LEI:
- 2138008J191VLSGY5A09
- Country:
- Belgium
- Address:
- ALLÉE DE LA RECHERCHE 60, 1070 ANDERLECHT
- Website:
- https://www.ucb.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
UCB is a global biopharmaceutical company focused on the discovery and development of solutions for people living with severe diseases. The company's primary therapeutic areas are neurology and immunology, creating treatments for conditions affecting the central nervous system and autoimmune disorders. Operating under the principle "Inspired by Patients. Driven by Science," UCB is committed to innovation in healthcare. The company offers personalized patient support through its UCBCares® service and invests in pioneering life science technologies and companies through its corporate venture arm, UCB Ventures, to advance medical science and improve patient outcomes.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-09 20:00 |
Major Shareholding Notification
091025 EN Transparency notification FMR LLC.pdf
|
English | 349.1 KB | ||
| 2025-10-09 20:00 |
Major Shareholding Notification
091025 FR Notification de transparence FMR LLC.pdf
|
French | 304.7 KB | ||
| 2025-10-09 20:00 |
Major Shareholding Notification
091025 NL Transparantieverklaring FMR LLC.pdf
|
Dutch | 304.9 KB | ||
| 2025-08-12 20:00 |
Major Shareholding Notification
EN PR.pdf
|
English | 307.0 KB | ||
| 2025-08-12 20:00 |
Major Shareholding Notification
FR PR.pdf
|
French | 294.4 KB | ||
| 2025-08-12 20:00 |
Major Shareholding Notification
NL PR.pdf
|
Dutch | 289.3 KB | ||
| 2025-07-31 07:00 |
Interim / Quarterly Report
UCB PR HY 2025 ENG.pdf
|
English | 615.4 KB | ||
| 2025-07-31 07:00 |
Earnings Release
UCB PR HY 2025 FR.pdf
|
French | 590.2 KB | ||
| 2025-07-31 07:00 |
Interim / Quarterly Report
UCB PR HY 2025 NL.pdf
|
Dutch | 983.3 KB | ||
| 2025-07-31 07:00 |
Interim / Quarterly Report
UCB_Half-Year_2025_Report-EN-FINAL.pdf
|
English | 1.5 MB | ||
| 2025-07-31 07:00 |
Management Reports
UCB_Half-Year_2025_Report-FR-FINAL.pdf
|
French | 1.5 MB | ||
| 2025-07-31 07:00 |
Interim / Quarterly Report
UCB_Half-Year_2025_Report-NL-FINAL.pdf
|
Dutch | 1.5 MB | ||
| 2025-07-10 20:00 |
Major Shareholding Notification
EN FMR 10.07.2025.pdf
|
English | 348.5 KB | ||
| 2025-07-10 20:00 |
Major Shareholding Notification
FR FMR 10.07.2025.pdf
|
French | 304.0 KB | ||
| 2025-07-10 20:00 |
Major Shareholding Notification
NL FMR 10.07.2025.pdf
|
Dutch | 304.0 KB |
Automate Your Workflow. Get a real-time feed of all UCB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for UCB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for UCB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-28 | Caeymaex Emmanuel | Executive member | Sell | 2,597 | 389,420.15 EUR |
| 2025-04-22 | Peacock Jonathan | Board | Buy | 674 | 93,247.90 EUR |
| 2025-04-01 | Lund- Jürgensen Kirsten | Executive member | Buy | 2,143 | N/A |
| 2025-03-04 | Caeymaex Emmanuel | Executive member | Sell | 7,000 | 1,362,568.51 EUR |
| 2025-03-04 | Caeymaex Emmanuel | Executive member | Buy | 7,000 | 532,630.00 EUR |
| 2025-03-03 | Caeymaex Emmanuel | Executive member | Sell | 4,100 | 769,226.28 EUR |
| 2025-03-03 | Caeymaex Emmanuel | Executive member | Sell | 2,822 | 522,643.25 EUR |
| 2025-03-03 | Caeymaex Emmanuel | Executive member | Buy | 4,100 | 271,338.00 EUR |
| 2025-03-03 | Caeymaex Emmanuel | Executive member | Buy | 2,822 | 198,273.72 EUR |
| 2025-02-28 | Caeymaex Emmanuel | Executive member | Sell | 7,000 | 1,260,465.07 EUR |
Peer Companies
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}